CHELSIE MONROE: Open Payments
NPI 1104235761 · LITTLETON, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$417,359 in 651 payments from 18 companies in 2025. Trend: 2023 $240,634 · 2024 $254,391 · 2025 $417,359
Speaker / faculty: $232,136Consulting: $66,977Honoraria: $60,151Travel & lodging: $44,928Food & beverage: $13,075Education: $91
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 139 | $105,417 |
| Teva Pharmaceuticals USA, Inc. | 80 | $79,038 |
| Axsome Therapeutics, Inc. | 124 | $72,878 |
| ABBVIE INC. | 75 | $49,255 |
| Alkermes, Inc. | 86 | $43,249 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 51 | $26,580 |
| E.R. Squibb & Sons, L.L.C. | 51 | $25,156 |
| Otsuka America Pharmaceutical, Inc. | 24 | $14,822 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $298 |
| Janssen Scientific Affairs, LLC | 2 | $190 |
Products named: INGREZZA, Auvelity, AUSTEDO XR, VRAYLAR, LYBALVI, UZEDY, CAPLYTA, COBENFY.
Industry payments across CO — which companies pay providers there.
